DOCSLIB.ORG

Licht Archives of General Psychiatry 65(12)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Licht Archives of General Psychiatry 65(12) VU Research Portal Association between major depressive disorder and heart rate variability in the Netherlands Study of Depression and Anxiety (NESDA). Licht, C.M.M.; de Geus, E.J.C.; Zitman, F.G.; Hoogendijk, W.J.G.; van Dyck, R.; Penninx, B.W.J.H. published in Archives of General Psychiatry 2008 DOI (link to publisher) 10.1001/archpsyc.65.12.1358 document version Publisher's PDF, also known as Version of record Link to publication in VU Research Portal citation for published version (APA) Licht, C. M. M., de Geus, E. J. C., Zitman, F. G., Hoogendijk, W. J. G., van Dyck, R., & Penninx, B. W. J. H. (2008). Association between major depressive disorder and heart rate variability in the Netherlands Study of Depression and Anxiety (NESDA). Archives of General Psychiatry, 65(12), 1358-1367. https://doi.org/10.1001/archpsyc.65.12.1358 General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal ? Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. E-mail address: [email protected] Download date: 25. Sep. 2021 ORIGINAL ARTICLE Association Between Major Depressive Disorder and Heart Rate Variability in the Netherlands Study of Depression and Anxiety (NESDA) Carmilla M. M. Licht, MSc; Eco J. C. de Geus, PhD; Frans G. Zitman, MD, PhD; Witte J. G. Hoogendijk, MD, PhD; Richard van Dyck, MD, PhD; Brenda W. J. H. Penninx, PhD Context: It has been hypothesized that depression is as- trol, as indexed by respiratory sinus arrhythmia (RSA), were sociated with lower heart rate variability and decreased car- measured during 11⁄2 hours of ambulatory recording of elec- diac vagal control. This may play an important role in the trocardiograms and thorax impedance. Multivariate analy- risk of cardiovascular disease among depressed individuals. ses were conducted to compare SDNN and RSA across de- pression groups after adjustment for demographics, health, Objective: To determine whether heart rate variability lifestyle, comorbid anxiety, and psychoactive medication. was lower in depressed individuals than in healthy con- trols in a large adult sample. Results: Individuals with remitted and current MDD had a lower mean SDNN and RSA compared with controls Design: Cross-sectional analyses from a large depres- (SDNN, 3.1-5.7 milliseconds shorter, PՅ.02; RSA, 5.1- sion cohort study. 7.1 milliseconds shorter, PϽ.001; effect size, 0.125- 0.269). Comorbid anxiety and lifestyle did not reduce these Setting: The Netherlands Study of Depression and associations. However, accounting for psychoactive medi- Anxiety. cation removed the association with SDNN and strongly attenuated the association with RSA. Depressed individu- Participants: Two thousand three hundred seventy- three individuals (mean age, 41.8 years; 66.8% female) als who were using selective serotonin reuptake inhibi- who participated in the Netherlands Study of Depres- tors, tricyclic antidepressants, or other antidepressants had sion and Anxiety. Included were 524 controls, 774 in- significantly shorter SDNNs and RSAs (effect size, 0.207- dividuals with a diagnosis of major depressive disorder 0.862) compared with controls and depressed individuals (MDD) earlier in life (remitted MDD), and 1075 indi- not taking medication. viduals with current MDD based on the Composite In- ternational Diagnostic Interview. This sample was suf- Conclusions: This study shows that depression is asso- ficiently powered to examine the confounding effects of ciated with significantly lowered heart rate variability. lifestyle, comorbid anxiety, and antidepressants. However, this association appears to be mainly driven by the effect of antidepressants. Main Outcome Measures: The standard deviation of normal-to-normal beats (SDNN) and cardiac vagal con- Arch Gen Psychiatry. 2008;65(12):1358-1367 EPRESSION RESULTS IN UN- attention has been focused on low car- favorable health out- diac vagal control, which may impair so- comes, such as cardiovas- cial engagement and flexible adjustment cular morbidity and to environmental demands19-22 and may be mortality.1-6 Alterations in a major determinant of a reduction in heart Dthe autonomic nervous system have been rate variability. hypothesized to be an underlying physi- Cardiac vagal control can be assessed by ological mechanism that may partly ex- examining heart rate variability, particu- plain these unfavorable health outcomes larly that in the respiratory frequency range. among depressed persons.7-11 Such alter- This part of heart rate variability is also ations are believed to reduce heart rate vari- known as respiratory sinus arrhythmia ability, a well-known prognostic risk factor (RSA).23 In a recent meta-analysis, Rotten- for cardiovascular disease (eg, myocar- berg22 examined the association between de- dial infarct and arrhythmias), and mor- pression and RSA. The meta-analysis sum- Author Affiliations are listed at tality.12-18 In research on autonomic ner- marized 13 studies that reported on RSA the end of this article. vous system correlates of depression, most measures, with a total of 312 depressed sub- (REPRINTED) ARCH GEN PSYCHIATRY/ VOL 65 (NO. 12), DEC 2008 WWW.ARCHGENPSYCHIATRY.COM 1358 Downloaded from www.archgenpsychiatry.com at Vrije Universiteit, on December 1, 2010 ©2008 American Medical Association. All rights reserved. jects and 374 controls. Depressed persons were found to in all participants using the 30-item Inventory of Depressive have a significantly shorter RSA, though the summarized Symptomatology, Self-Report (IDS-SR).42 effect size was small to medium according to Cohen con- To test whether SDNN and RSA differed across persons with ventions (d=0.332). As pointed out by Rottenberg, data and without a depressive disorder, 3 distinct depression groups collection and analysis differed considerably among the were created for the present study: 524 controls with no his- tory of depression or anxiety disorders and low scores on a de- studies and only a few of them had the required sample pressive symptom questionnaire (IDS-SR score Յ14); 774 per- size to address confounding by lifestyle (smoking, use of sons with a major depressive disorder (MDD) diagnosis alcohol, high body mass index, and low physical activity) (according to CIDI) earlier in life but not within the past 6 and comorbid anxiety. However, many of these factors— months (remitted MDD group); and 1075 persons with a CIDI- substance use, low physical activity, and comorbid anxi- confirmed MDD diagnosis within the past 6 months (72% had ety—occur frequently in depression and have been asso- experienced a depressive episode in the past month) (current ciated with decreased cardiac vagal control.24,25 Finally, MDD group). The remaining 608 individuals were excluded antidepressants are a particularly relevant source of po- from the analyses: 128 controls had an IDS-SR score greater tential confounding when examining the association be- than 14; 404 patients had an anxiety disorder, minor depres- tween depression and cardiac vagal control. The suppres- sion, or dysthymia in absence of an MDD diagnosis; and 76 had missing physiological data owing to equipment failure during sive effects of tricyclic antidepressants (TCAs) on assessment or poor electrocardiogram quality. autonomic function are already well established.26-31 The effect of other antidepressants on autonomic function, how- ever, are not as well studied and inconsistent results have MEASUREMENTS been reported.29,32-34 The present study reports cross- sectional analyses from a large depression cohort study The baseline assessment consisted of a blood sample, cognitive computer task, medical examination, psychiatric interview, sa- (Netherlands Study of Depression and Anxiety [NESDA], liva collection, and administration of several written question- N=2981). We examined whether heart rate variability, as naires concerning, eg, mood, lifestyle, medical history, and medi- indexed by the standard deviation of normal-to-normal cation use. In this way, extensive information about psychological, beats (SDNN), and cardiac vagal control, as indexed by biological, physical, and demographic determinants were col- RSA derived from peak-valley estimation,35,36 differed be- lected. The study protocol was approved by the ethics review tween depressed individuals and healthy controls. The board of the VU University Medical Center and subsequently by study was sufficiently powered to examine the extent to local review boards of each participating center. All participants which these associations are confounded by lifestyle, co- signed an informed consent at baseline. morbid anxiety, and effect of antidepressants. PHYSIOLOGICAL MEASUREMENTS METHODS Physiological recording was performed using the Vrije Univer- siteit Ambulatory Monitoring System (VU-AMS; Vrije Univer- PARTICIPANTS siteit, Amsterdam, the Netherlands). The VU-AMS is a light- weight portable device that records
Load more

Recommended publications
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Educationally Intervening the Use of Potentially Harmful Medication Among Residents in Institutional Settings
    Department of General Practice and Primary Health Care Faculty of Medicine University of Helsinki Finland EDUCATIONALLY INTERVENING THE USE OF POTENTIALLY HARMFUL MEDICATION AMONG RESIDENTS IN INSTITUTIONAL SETTINGS Anna-Liisa Juola Academic dissertation To be presented, with the permission of the Faculty of Medicine, University of Helsinki, for public examination in Auditorium XII, Fabianinkatu 33, on 2nd February 2018, at 12 noon Helsinki, Finland 2018 Supervisors Professor Kaisu Pitkälä, MD, PhD University of Helsinki, Department of General Practice and Primary Health Care Helsinki, Finland Mikko Björkman, MD, PhD University of Helsinki, Department of Medicine, Division of Geriatrics Helsinki, Finland Reviewers Professor Esa Leinonen, MD, PhD University of Tampere, Department of Psychiatry Tampere, Finland Adjunct Professor Juha Puustinen, MD, PhD University of Helsinki, Division of Pharmacology and Pharmacotherapy Helsinki, Finland Satakunta Hospital District, Unit of Neurology Pori, Finland Opponent Adjunct Professor Raimo Isoaho, MD, MPH, PhD University of Turku, Department of General Practice Turku, Finland City of Vaasa, Social and Health Services Vaasa, Finland Cover graphics Vesa Juola Untitled 2017 ISBN 978-951-51-4032-6 (nid.) ISBN 978-951-51-4033-3 (PDF) Unigrafia Helsinki 2018 To Vesa with love Contents Abbreviations 7 Definitions 8 List of original publications 9 Abstract 10 Tiivistelmä (Finnish Abstract) 13 1 Introduction 17 2 Review of the literature 19 2.1 Ageing and medication 19 2.1.1 Pharmacokinetics
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,828,437 B2 Sundberg Et Al
    USOO8828437B2 (12) United States Patent (10) Patent No.: US 8,828,437 B2 Sundberg et al. (45) Date of Patent: *Sep. 9, 2014 (54) THERMOGELLING ANAESTHETIC USPC .......................................................... 424/484 COMPOSITIONS (58) Field of Classification Search None (71) Applicant: Pharmanest AB, Solna (SE) See application file for complete search history. (72) Inventors: Mark Sundberg, Arsta (SE); Arne (56) References Cited Brodin, Sodertalje (SE); Nils Kallberg, Taby (SE) U.S. PATENT DOCUMENTS (73) Assignee: Pharmanest AB, Solna (SE) 8,663,688 B2* 3/2014 Fernandez et al. ............ 424/487 2004/O220283 A1 11/2004 Zhang et al. 2005/0O27.019 A1 2/2005 Zhang et al. (*) Notice: Subject to any disclaimer, the term of this 2007/0298.005 A1 12, 2007 Thibault patent is extended or adjusted under 35 2008. O15421.0 A1 6/2008 Jordan et al. U.S.C. 154(b) by 0 days. 2012fO294907 A1 11/2012 Zhang et al. This patent is Subject to a terminal dis claimer. FOREIGN PATENT DOCUMENTS AU 2006201233 B2 10, 2007 (21) Appl. No.: 14/172,794 EP O517160 A1 12, 1992 EP 1629852 A2 3, 2006 (22) Filed: Feb. 4, 2014 KR 2002OO13248 A 2, 2002 (65) Prior Publication Data (Continued) OTHER PUBLICATIONS US 2014/O155.434 A1 Jun. 5, 2014 Written Opinion, Intellectual Property Office of Singapore, from the Related U.S. Application Data corresponding Singapore Application No. 201206824-3, Jul. 19. (63) Continuation of application No. 13/638.511, filed as 2013. application No. PCT/EP2011/055009 on Mar. 31, Notification of First Office Action, China Intellectual Property 2011. Office, from the corresponding Chinese Application No.
    [Show full text]
  • ZUSAMMENFASSUNG DER MERKMALE DES ARZNEIMITTELS & PACKUNGSBEILAGE SEVORANE 1. BEZEICHNUNG DES ARZNEIMITTELS Sevorane Quick Fi
    ZUSAMMENFASSUNG DER MERKMALE DES ARZNEIMITTELS & PACKUNGSBEILAGE SEVORANE 1. BEZEICHNUNG DES ARZNEIMITTELS Sevorane Quick Fill 100%, Flüssigkeit zur Herstellung eines Dampfs zur Inhalation 2. QUALITATIVE UND QUANTITATIVE ZUSAMMENSETZUNG Sevofluran 100% Vollständige Auflistung der sonstigen Bestandteile siehe Abschnitt 6.1. 3. DARREICHUNGSFORM Flüssigkeit zur Herstellung eines Dampfs zur Inhalation Eigenschaften: Sevoflurane ist ein fluoriertes Derivat von Methylisopropylether. Sevoflurane wird chemisch als Fluormethyl 2,2,2-trifluor-1-(trifluormethyl) Ethylether identifiziert und hat ein Molekulargewicht von 200,05. Sevoflurane besitzt folgende physikalische und chemische Eigenschaften: Siedepunkt bei 760 mm Hg 58,6°C Dichte bei 20°C 1,520-1,525 Dampfspannung (errechnet) in mm HG** 157 mm Hg bei 20°C 197 mm Hg bei 25°C 317 mm Hg bei 36°C ** Gleichung für die (errechnete) Dampfspannung, mm Hg: Log10Pvap = A+B/T wobei: A = 8,086 B = -1726,68 T = °C + 273,16°K (Kelvin) Verteilungskoeffizienten bei 37°C Blut/Gas 0,63-0,69 Wasser/Gas 0,36 Olivenöl/Gas 47,2-53,9 Gehirn/Gas 1,15 Mittlere Verteilungskoeffizienten, Bestandteil/Gas bei 25°C für Polymere, die häufig bei medizinischen Anwendungen angewendet werden; Leitfähiger Gummi 14,0 Butylkautschuk 7,7 Polyvinylchlorid 17,4 Polyethylen 1,3 Sevoflurane ist nicht entflammbar und nicht explosiv entsprechend der Norm 601-2-13 der Internationalen Elektrotechnik-Kommission. Sevoflurane ist eine klare und farblose Flüssigkeit. ZMA = Leaflet (DE) 1/17 printed on 4-Feb-19 16:03 Sevoflurane ist nicht reizend. Es ist mischbar mit Ethanol, Ether, Chloroform und Benzol und im Wasser schwach löslich. Abbau von Sevofluran Sevoflurane ist stabil, wenn es bei normalen Lichtbedingungen gelagert wird.
    [Show full text]
  • Holland & Knight
    FILED 1/14/2020 DOCUMENT NO. 00281-2020 Holland & Knight FPSC - COMMISSION CLERK 315 South Calhoun Street, Suite 600 I Tallahassee, FL 32301 IT 850.224.7000 I F 850.224.8832 Holland & Knight LLP I www.hklaw.com D. Bruce May, Jr. (850) 425-5607 [email protected] January 14, 2020 Adam Teitzman Office of Commission Clerk Florida Public Service Commission 2540 Shumard Oak Boulevard Tallahassee, FL 32399-0850 Re: Docket 20190194-WS -- Application for original water and wastewater and approval of initial rates, charges and standard service agreements in Lee County, by CPI Citrus Park Utility TRS, L.L.C. Dear Mr. Teitzman: CPI Citrus Park Utility TRS, L.L.C. (the "Utility") respectfully submits its responses to Commission Staffs letter dated November 21, 2019 ("Staff Letter"), which identified certain deficiencies to the Utility's application submitted on October 23, 2019. For ease ofreference, the deficiencies set forth in the Staff Letter are repeated verbatim herein, with the Utility's response immediately following each item. I. Contact info. Rule 25-30.033(1 )(c), Florida Administrative Code (F.A.C.), requires the utility's name, address, telephone number, Federal Employer Identification Number, authorized representative, and, if available, email address and fax number. Please provide the Utility's email, fax number, and telephone number, if different from the telephone number provided for Mr. David Daniel, as a contact for the application. Response: The Utility's email address is: [email protected]. The relevant contact information regarding the application is as follows: Steven P. Adler 12629 New Brittany Blvd.
    [Show full text]
  • Evaluation of Carcinogenicity Studies of Medicinal Products for Human Use Authorised Via the European Centralised Procedure
    Regulatory Toxicology and Pharmacology xxx (2011) xxx–xxx Contents lists available at ScienceDirect Regulatory Toxicology and Pharmacology journal homepage: www.elsevier.com/locate/yrtph Evaluation of carcinogenicity studies of medicinal products for human use authorised via the European centralised procedure (1995–2009) ⇑ Anita Friedrich a, , Klaus Olejniczak b a Granzer Regulatory Consulting and Services, Zielstattstrasse 44, 81379 Munich, Germany b Federal Institute for Drugs and Medical Devices, Kurt-Georg-Kiesinger-Allee 3, 53175 Bonn, Germany article info abstract Article history: Carcinogenicity data of medicinal products for human use that have been authorised via the European Received 25 October 2010 centralised procedure (CP) between 1995 and 2009 were evaluated. Carcinogenicity data, either from Available online xxxx long-term rodent carcinogenicity studies, transgenic mouse studies or repeat-dose toxicity studies were available for 144 active substances contained in 159 medicinal products. Out of these compounds, 94 Keywords: (65%) were positive in at least one long-term carcinogenicity study or in repeat-dose toxicity studies. Medicinal products Fifty compounds (35%) showed no evidence of a carcinogenic potential. Out of the 94 compounds with Carcinogenicity positive findings in either carcinogenicity or repeat-dose toxicity studies, 33 were positive in both mice Rodents and rats, 40 were positive in rats only, and 21 were positive exclusively in mice. Long-term carcinogenic- ity studies in two rodent species were available for 116 compounds. Data from one long-term carcinoge- nicity study in rats and a transgenic mouse model were available for eight compounds. For 13 compounds, carcinogenicity data were generated in only one rodent species. One compound was exclu- sively tested in a transgenic mouse model.
    [Show full text]
  • Summary of Product Characteristics
    Health Products Regulatory Authority Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Versatis 700 mg medicated plaster 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 10 cm x 14 cm plaster contains 700 mg lidocaine (equivlent to 5% w/w) Excipients with known effect: Methyl parahydroxybenzoate (E218) 14 mg Propyl parahydroxybenzoate (E216) 7 mg Propylene glycol (E1520) 700 mg For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Medicated plaster White hydrogel plaster containing adhesive material, which is applied to a non-woven polyethylene terephthalate backing embossed with “Lidocaine 5%” and covered with a polyethylene terephthalate film release liner. 4 CLINICAL PARTICULARS 4.1 Therapeutic Indications Versatis is indicated for the symptomatic relief of neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia, PHN) in adults. 4.2 Posology and method of administration Adults and elderly patients The painful area should be covered with the plaster once daily for up to 12 hours within a 24 hours period. Only the number of plasters that are needed for an effective treatment should be used. When needed, the plasters may be cut into smaller sizes with scissors prior to removal of the release liner. In total, not more than three plasters should be used at the same time. The plaster must be applied to intact, dry, non-irritated skin (after healing of the shingles). Each plaster must be worn no longer than 12 hours. The subsequent plaster-free interval must be at least 12 hours. The plaster can be applied during the day or during the night.
    [Show full text]
  • Scandonest EMEA/H/A30/1455
    Annex I List of medicinal products and presentations 1 Member State Marketing authorisation Invented Name Strength Pharmaceutical Route of Content EU/EEA holder form administration (concentration) SCANDONEST 3% Septodont GmbH OHNE Felix-Wankel-Str. 9 Solution for Austria VASOKONSTRIKTOR 3% Dental use 30 mg/ml 53859 Niederkassel-Mondorf injection - Germany ZYLINDERAMPULLEN Septodont NV-SA SCANDONEST 3% 87 Avenue de la Constitution Solution for Belgium SANS 3% Dental use 30 mg/ml B-1083 Bruxelles injection VASOCONSTRICTEUR Belgium Septodont 58, rue du Pont de Créteil SCANDONEST 30 Solution for Bulgaria 30 mg/ml Dental use 30 mg/ml 94100 Saint-Maur-des-Fossés MG/ML injection France Apolonia d.o.o. SCANDONEST 30 Dental use Dubrova 308 Solution for Croatia mg/ml otopina za 30 mg/ml Perineural use 30 mg/ml 52220 Labin injection injekciju Submucosal use Croatia Spécialités Septodont Dental use 58, rue du Pont de Créteil Solution for Denmark SCANDONEST 30 mg/ml Perineural use 30 mg/ml 94100 Saint-Maur-des-Fossés injection Submucosal use France Septodont Solution for Dental use 58, rue du Pont de Créteil Estonia SCANDONEST 30 mg/ml injection in Perineural use 30 mg/ml 94100 Saint-Maur-des-Fossés cartridge Submucosal use France Septodont 58, rue du Pont de Créteil Solution for Dental use Finland SCANDONEST 30 mg/ml 30 mg/ml 94100 Saint-Maur-des-Fossés injection France Laboratoires Septodont SCANDONEST 30 58, rue du Pont de Créteil Dental use MG/ML, SOLUTION Solution for France 94107 Saint-Maur-des-Fossés 30 mg/ml Perineural use 30 mg/ml INJECTABLE À injection Cedex Submucosal use USAGE DENTAIRE France 2 Member State Marketing authorisation Invented Name Strength Pharmaceutical Route of Content EU/EEA holder form administration (concentration) Septodont GmbH SCANDONEST 3% Felix-Wankel-Str.
    [Show full text]
  • 2Ull/121Uo2 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date Χ / A 1 6 October 2011 (06.10.2011) W O 2Ull/121Uo2 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/06 (2006.01) A61K 31/445 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 9/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP201 1/055025 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 31 March 201 1 (3 1.03.201 1) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 1050322-5 1 April 2010 (01 .04.2010) SE kind of regional protection available): ARIPO (BW, GH, 61/325,425 19 April 2010 (19.04.2010) US GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, (71) Applicant (for all designated States except US): Phar- TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, manest AB [SE/SE]; Karolinska Institutet Science Park, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Nobels vag 3, S-171 65 Solna (SE).
    [Show full text]
  • Australian Statistics on Medicines 2009
    Australian Statistics on Medicines 2009 Australian Statistics on Medicines 2009 Acknowledgments Prepared by Vanna Mabbott, Maxine Robinson and Quinton Brennan of the Drug Utilisation Sub-Committee Secretariat. We would like to thank the following people for their help in the access and provision of data and information used in this report: • The World Health Organization Collaborating Centre for Drug Statistics Methodology. • Jess Dalla, Jennifer Haigh and Zoe Holdenson, Special Access Programs and Special Access Programs 2, Department of Health and Ageing. • Elspeth Kay, Adverse Drug Reaction Advisory Committee, Therapeutic Goods Administration. • Jacqueline Rek, Australian Institute of Health and Welfare. Australian Statistics on Medicines 2009 Print ISBN: 978-1-74241-557-4 Online ISBN: 978-1-74241-558-1 Publications approval number: D0514 Paper-based publications © Commonwealth of Australia 2011 This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given the specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the Communications Branch, Department of Health and Ageing, GPO Box 9848, Canberra ACT 2601, or via e-mail to [email protected].
    [Show full text]
  • Scandonest EMEA/H/A30/1455
    Annex III Product information Note: This product information is the outcome of the referral procedure to which this Commission decision relates. The product information may be subsequently updated by the Member State competent authorities, in liaison with the reference Member State, as appropriate, in accordance with the procedures laid down in Chapter 4 of Title III of Directive 2001/83/EC. 11 SUMMARY OF PRODUCT CHARACTERISTICS 12 1. NAME OF THE MEDICINAL PRODUCT {Scandonest and associated names (see Annex I) strength pharmaceutical form} [See Annex I - To be completed nationally] 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml solution for injection contains 30 mg of mepivacaine hydrochloride. Each cartridge of 1.7 ml of solution for injection contains 51 mg of mepivacaine hydrochloride. Each cartridge of 2.2 ml of solution for injection contains 66 mg of mepivacaine hydrochloride. Excipient(s) with known effect Each ml contains 0.11 mmol of sodium (2.467 mg/ml). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection. Clear and colourless solution. PH: 6.1-6.7 4. CLINICAL PARTICULARS 4.1 Therapeutic indications {Scandonest and associated names (see Annex I) strength pharmaceutical form} is a local anaesthetic indicated for the local and loco-regional anaesthesia in dental surgery in adults, adolescents and children above 4 years of age (c.a. 20 kg of body weight). 4.2 Posology and method of administration The medicinal product should only be used by or under the supervision of dentists, stomatologists or other clinicians sufficiently trained and familiar with diagnosis and treatment of systemic toxicity.
    [Show full text]
  • Inventory of the Most Important Pharmaceutical Compounds
    018530 - SWITCH Sustainable Water Management in the City of the Future Integrated Project Global Change and Ecosystems Deliverable 4.1.2 Listing the most important pharmaceutical compounds from various therapeutic groups and the testing and validation of analytical methods for the selected compounds 4.1.2 A. Pre-selection of representative compounds for laboratory degradation tests 4.1.2 B Survey of the mostly used pharmaceutical compounds and hormones in the West Bank/Palestine 4.1.2 C. Estrogens in aquatic environment: A review. Due date of deliverable: 14 th February 2007 Actual submission date: 14 th February 2007 Start date of project: 1 February 2006 Duration: 60 months Authors : Katarzyna Kujawa-Roeleveld, Ime Akanyeti WU, Environmental Technology, Wageningen, The Netherlands Nidal Mahmoud, Water Studies Institute (WSI), Birzeit University, The West Bank, Palestine Wenxin Shi, IHE-UNESCO, Delft, The Netherlands Final Version Reviewer: Adriaan Mels Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public Pu PP Restricted to other programme participants (including the Commission Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) 1 SWITCH Deliverable Briefing Note (months 0-12) SWITCH Document Deliverable 4.1.2 consists of three parts: (A) Pharmaceutical compounds in environment Pre-selection of representative compounds for laboratory degradation tests (B) Survey of the mostly used pharmaceutical compounds and hormones in the West Bank/ Palestine (C) Estrogens in aquatic environment: A review Audience This document is targeted at scientists, engineers and policy makers.
    [Show full text]